Jupiter Life Line Hospitals (JLHL) Q4 25/26 earnings summary

Executive summary

• Achieved two major milestones in FY26: acquisition of land at BKC for a 400-bed hospital and early operationalization of Dombivli hospital, expanding presence to four hospitals in MMR, two in Pune, and one in Indore.

• Approved audited consolidated and standalone financial results for the year and quarter ended March 31, 2026, with unmodified audit opinions from statutory auditors.

• Interim dividend of 10% per equity share (Rs. 1 per share) declared for FY 2025-26, record date May 22, 2026.

• Board approved a 1:5 stock split, reducing face value from Rs. 10 to Rs. 2 per share, subject to shareholder approval.

• Dombivli hospital was delivered ahead of schedule and on budget, but its initial ramp-up led to operating losses and higher depreciation in Q4.

Financial highlights

• FY26 total income rose to ₹1,499.8 Cr, up 15.2% year-over-year; EBITDA increased 14.4% to ₹343.3 Cr.

• PAT for FY26 was ₹194.2 Cr, nearly flat year-over-year due to new labor code changes and Dombivli ramp-up losses.

• Q4FY26 revenue from operations grew 15.1% YoY and 6.5% sequentially; EBITDA margin for FY26 remained stable at 23.0%.

• Consolidated revenue for FY 2025-26 was Rs. 14,997.87 million, up from Rs. 13,024.02 million year-over-year.

• Earnings per share (consolidated, basic and diluted) for FY 2025-26 was Rs. 29.59.

Outlook and guidance

• Scaling bed capacity to 2,900 with new projects in Dombivli, Pune II, Mira-Bhayandar, and BKC, with phased commissioning to optimize capital deployment.

• BKC hospital to be a 400-bed multispecialty quaternary care facility in a prime Mumbai location.

• Interim dividend declared; record date set for May 22, 2026.

• Stock split expected to enhance share liquidity and affordability for retail investors.